One early study using BRL35135, an esterified prodrug that is quickly converted to BRL37344 in vivo, showed that chronic (10 days) administration of BRL35135 in obese subjects improves glycemic control, reduces insulin resistance (improved glucose tolerance profiles), and increases insulin‐mediated body glucose disposal under hyperinsulinemic‐euglycemic clamps.35 Here, INS is linked to Insulin resistance.